SCHEMBL3390191

SCHEMBL3390191

CC(C)OC(=O)c1[c]cc2ccccc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
LMNA P02545 2/20 0.48
TP53 P04637 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 3/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PDCD1 Q15116 1/20 0.42
CD274 Q9NZQ7 1/20 0.42
CA12 O43570 6/20 0.42
CA1 P00915 6/20 0.42
CA2 P00918 6/20 0.42
CA7 P43166 6/20 0.42
CA9 Q16790 6/20 0.42
CA14 Q9ULX7 6/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3391383 0.81 HSP90AA1 (0.46) KDM4ELMNAALDH1A1HPGDHSD17B10
SCHEMBL293511 0.75 ALDH1A1 (0.38) KDM4ELMNAALDH1A1CYP1A2CYP2C19
SCHEMBL5748265 0.73 KDM4E (0.44) KDM4ELMNAL3MBTL1ALDH1A1CYP2C19
SCHEMBL3899987 0.73 IDO1 (0.42) KDM4EALDH1A1CYP1A2CYP2C19MEN1
SCHEMBL130469 0.73 PDCD1 (0.47) KDM4ELMNATP53L3MBTL1ALDH1A1
SCHEMBL23997992 0.71 NPC1 (0.64) KDM4ELMNATP53L3MBTL1ALDH1A1
SCHEMBL6952994 0.71 CA12 (0.55) KDM4ELMNAL3MBTL1ALDH1A1NPC1
SCHEMBL22263726 0.71 KDM4E (0.44) KDM4ELMNATP53L3MBTL1ALDH1A1
SCHEMBL6950001 0.70 CA12 (0.53) KDM4ELMNATP53L3MBTL1ALDH1A1
SCHEMBL6231650 0.70 CA12 (0.60) KDM4ELMNATP53L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1716160-B1 NOVEL INHIBITORS OF CHYMASE JANSSEN PHARMACEUTICA NV (BE) 2010-12-29 EP claimed
US-9730449-B2 Thiazole compound and its use in pest control SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-08-15 US disclosed
EP-3093286-A1 THIAZOLE COMPOUNDS AND PEST CONTROL APPLICATIONS THEREOF Sumitomo Chemical Co., Ltd (JP) 2016-11-16 EP disclosed
US-20160324155-A1 THIAZOLE COMPOUND AND ITS USE IN PEST CONTROL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-11-10 US disclosed
EP-1716160-B1 NOVEL INHIBITORS OF CHYMASE JANSSEN PHARMACEUTICA NV (BE) 2010-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160324155-A1 THIAZOLE COMPOUND AND ITS USE IN PEST CONTROL TRPA1, NAT1, TAS2R1 KDM4E 2535/4885LMNA 4191/4885TP53 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.